Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ian Malburg

Pain Medicine Manhattan, KS Medical Doctor

NPI 1821384975 CMS profile 128693

1823 College Ave, Manhattan, KS 66502

Open in the dashboard

General payments

$2,121

40 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ian Malburg of Manhattan, KS is reported in the CMS Open Payments database as having received $2,121 across 40 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 49th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $346 10
2024 General $138 3
2023 General $1,059 17
2022 General $532 9
2019 General $46 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ian Malburg
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Ian Malburg were reported at $346. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Ian Malburg Pain Medicine median Middle half National median
2019 $46 $498 $126–$1,682 $163
2020 $0 $284 $80–$910 $114
2021 $0 $399 $112–$1,219 $132
2022 $532 $455 $137–$1,484 $149
2023 $1,059 $484 $128–$1,495 $160
2024 $138 $498 $131–$1,540 $164
2025 $346 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nevro Corp. $422 6 payments
  2. Saluda Medical Americas, Inc. $415 5 payments
  3. Boston Scientific Corporation $329 8 payments
  4. Nalu Medical, Inc. $320 3 payments
  5. Spinal Simplicity, LLC $144 2 payments
  6. SPR Therapeutics, Inc $136 6 payments
  7. Abbott Laboratories $109 3 payments
  8. Relievant Medsystems, Inc. $93 1 payment
  9. Medtronic USA, Inc. $46 1 payment
  10. GRT US Holding, Inc. $42 2 payments
  11. Other $64 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,121 40 payments
Products named General payments · program years 2019–2025
  1. Senza $422 6 payments
  2. Nalu Neurostimulation System $320 3 payments
  3. Evoke SCS $272 2 payments
  4. HA MINUTEMAN G3-R $144 2 payments
  5. Evoke $143 3 payments
  6. Intracept Intracept Access Instruments - Additional VB (Gen 3)_NMOD $138 3 payments
  7. SPRINT PNS System $136 6 payments
  8. Intracept Pain $93 1 payment
  9. Intracept Pain $93 1 payment
  10. PROCLAIM $84 2 payments
  11. Other $268 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

401

Median for Pain Management: 951

Drug cost

$7,722

Median for Pain Management: $26,034

Branded share of claims

30.4%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 43 $2,009
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 67 $1,831
Gabapentin Generic 86 $971
Fentanyl Generic 13 $964
Pregabalin Generic 40 $687
Morphine Sulfate Generic 11 $352
Morphine Sulfate Er Morphine Sulfate Brand 12 $290
Tramadol Hcl Generic 45 $276
Tizanidine Hcl Generic 56 $205
Baclofen Generic 13 $130

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$76,438

Medicare's payments for the services billed

Medicare patients

279

Average age 73

Services billed

1,108

176 women, 103 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 42%
Diabetes 33%
Chronic kidney disease 29%
Ischemic heart disease 27%
Atrial fibrillation 21%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

40 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record